MacroGenics, Inc, a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone301-251-5172
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$60.12 million
Profitability
Miscellaneous
Employees364
Next Earnings Date2/25/2020 (Estimated)
OptionableOptionable
MacroGenics (NASDAQ:MGNX) Frequently Asked Questions
What is MacroGenics' stock symbol?
MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."
How were MacroGenics' earnings last quarter?
MacroGenics Inc (NASDAQ:MGNX) released its quarterly earnings data on Wednesday, November, 6th. The biopharmaceutical company reported ($0.91) EPS for the quarter, beating the consensus estimate of ($0.94) by $0.03. The biopharmaceutical company had revenue of $18.74 million for the quarter, compared to the consensus estimate of $23.33 million. MacroGenics had a negative net margin of 273.47% and a negative return on equity of 54.52%. View MacroGenics' Earnings History.
When is MacroGenics' next earnings date?
What price target have analysts set for MGNX?
12 brokers have issued 12-month price objectives for MacroGenics' shares. Their forecasts range from $14.00 to $50.00. On average, they expect MacroGenics' stock price to reach $25.38 in the next year. This suggests a possible upside of 219.2% from the stock's current price. View Analyst Price Targets for MacroGenics.
What is the consensus analysts' recommendation for MacroGenics?
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MacroGenics.
What are Wall Street analysts saying about MacroGenics stock?
Here are some recent quotes from research analysts about MacroGenics stock:
- 1. According to Zacks Investment Research, "MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland. " (11/1/2019)
- 2. HC Wainwright analysts commented, "Our 12-month, $39 price target for shares of MacroGenics is based on a 12-year DCF-driven sum-of-the-parts analysis. Our DCF is driven by: beta of 1.8, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 11.5%, and tax rate of 15% beginning in FY 2027. (18%), flotetuzumab (16%) together represent our full target. Risks potentially incurred investing in this stock include: clinical and development, financial, regulatory and reimbursement, and commercial." (5/2/2019)
Has MacroGenics been receiving favorable news coverage?
Media headlines about MGNX stock have trended very negative this week, according to InfoTrie. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. MacroGenics earned a news impact score of -3.2 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for MacroGenics.
Are investors shorting MacroGenics?
MacroGenics saw a increase in short interest in the month of October. As of October 15th, there was short interest totalling 4,370,000 shares, an increase of 6.3% from the September 15th total of 4,110,000 shares. Based on an average daily volume of 442,800 shares, the days-to-cover ratio is presently 9.9 days. Currently, 10.0% of the shares of the stock are short sold. View MacroGenics' Current Options Chain.
Who are some of MacroGenics' key competitors?
Some companies that are related to MacroGenics include Corcept Therapeutics (CORT), Eidos Therapeutics (EIDX), Alder Biopharmaceuticals (ALDR), Turning Point Therapeutics (TPTX), Supernus Pharmaceuticals (SUPN), Madrigal Pharmaceuticals (MDGL), Nabriva Therapeutics (NBRV), Gossamer Bio (GOSS), Epizyme (EPZM), Zymeworks (ZYME), Radius Health (RDUS), Enanta Pharmaceuticals (ENTA), Innoviva (INVA), BELLUS Health (BLUSF) and ArQule (ARQL).
What other stocks do shareholders of MacroGenics own?
Who are MacroGenics' key executives?
MacroGenics' management team includes the folowing people:
- Dr. Scott Koenig, CEO, Pres & Director (Age 67)
- Mr. James Karrels, Sr. VP, CFO & Sec. (Age 52)
- Dr. Ezio Bonvini, Sr. VP of Research & Chief Scientific Officer (Age 65)
- Mr. Eric Blasius Risser, Sr. VP of Bus. Devel. & Portfolio Management and Chief Bus. Officer (Age 46)
- Dr. Jon M. Wigginton, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 57)
Who are MacroGenics' major shareholders?
MacroGenics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (1.64%), Massachusetts Financial Services Co. MA (0.29%), Alps Advisors Inc. (0.20%), California Public Employees Retirement System (0.19%), Rhumbline Advisers (0.14%) and Campbell & CO Investment Adviser LLC (0.06%). Company insiders that own MacroGenics stock include Eric Blasius Risser, James Karrels, Jeffrey Stuart Peters, Jon Marc Wigginton, Lynn Cilinski, Matthew K Fust and Thomas Spitznagel. View Institutional Ownership Trends for MacroGenics.
Which major investors are selling MacroGenics stock?
MGNX stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB and Alps Advisors Inc.. Company insiders that have sold MacroGenics company stock in the last year include Eric Blasius Risser, Jeffrey Stuart Peters, Matthew K Fust and Thomas Spitznagel. View Insider Buying and Selling for MacroGenics.
Which major investors are buying MacroGenics stock?
MGNX stock was bought by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, Massachusetts Financial Services Co. MA, Campbell & CO Investment Adviser LLC, Tower Research Capital LLC TRC and Rhumbline Advisers. View Insider Buying and Selling for MacroGenics.
How do I buy shares of MacroGenics?
Shares of MGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is MacroGenics' stock price today?
One share of MGNX stock can currently be purchased for approximately $7.95.
How big of a company is MacroGenics?
MacroGenics has a market capitalization of $388.70 million and generates $60.12 million in revenue each year. The biopharmaceutical company earns $-171,450,000.00 in net income (profit) each year or ($4.19) on an earnings per share basis. MacroGenics employs 364 workers across the globe.View Additional Information About MacroGenics.
What is MacroGenics' official website?
How can I contact MacroGenics?
MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The biopharmaceutical company can be reached via phone at 301-251-5172.
MarketBeat Community Rating for MacroGenics (NASDAQ MGNX)
MarketBeat's community ratings are surveys of what our community members think about MacroGenics and other stocks. Vote "Outperform" if you believe MGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
